1. Home
  2. |Insights
  3. |DoD Expands Restrictions on Supply Chain for Certain Magnets, Tantalum, and Tungsten

DoD Expands Restrictions on Supply Chain for Certain Magnets, Tantalum, and Tungsten

Client Alert | 2 min read | 06.21.24

On May 30, 2024, the Department of Defense (DoD) issued a final rule implementing Section 844 of the Fiscal Year (FY) 2021 National Defense Authorization Act (NDAA) and Section 854 of the FY 2024 NDAA by amending DFARS 225.7018-2 and accompanying DFARS clause 252.225-7052, which restrict DoD from acquiring certain metals and magnets from “covered countries” of Iran, North Korea, Russia, and China, to prohibit even earlier inputs in the supply chain from occurring in these countries.  Despite comments discussing the infancy of the domestic market for many “covered materials”—defined as samarium-cobalt magnets, tantalum metals and alloys, tungsten metal powder, and tungsten heavy alloy or any finished or semi-finished component containing tungsten heavy alloy—the final rule expands the restrictions on sourcing covered materials from covered countries.  Currently, the rule requires that covered materials not be melted or produced in covered countries but, effective January 1, 2027, the updated rule prohibits covered materials being mined, refined, separated, melted or produced in one of the covered countries. The expansion of the focus of the prohibition all the way back to where these materials were mined is consistent with the U.S. government’s effort to develop the domestic industrial base for and encourage on-shoring of critical minerals, magnets, and metals.   

In addition, the final rule alters the applicability of the updated rule to commercially-available off-the-shelf (COTS) items, further limiting the COTS exception.  COTS items are exempt from the current prohibition unless they are 50% or more tungsten by weight.  Effective January 1, 2027, COTS items will be exempt from the updated prohibition unless they are 50% or more covered material (not just tungsten) by weight.   

Key Takeaways

Now that the final rule has clarified requirements, companies should consider:

  1. Reviewing their supply chains for prohibited covered materials and products.
  2. Identifying alternative sources for compliant products as required, given the expanded scope of the prohibition and the reduced applicability of the COTS exemption.
  3. Aggregating data to pursue and support a nonavailability determination by the government for a product or class of products if the company anticipates not having compliant product sources by January 1, 2027.

Insights

Client Alert | 3 min read | 11.17.26

CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs

On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.  ...